Vedanta Biosciences

Thank you to @CARB_X developers, partners, and investors who gathered in Vienna, Austria on April 10 for CARB-X's annual Investor Day! More than 20 developers in advanced product stages presented to downstream investors interested in supporting antimicrobial products.

If you have mild to moderate #ulcerativecolitis, and have not taken biologic medications or Janus Kinase (JAK) inhibitors, the VE202 study may be right for you. Learn more: bit.ly/3ZZ0FqD #sponsored #ulcerativecolitis #VE202 #UC

The Vedanta team is very excited to share our latest findings coming out of our successful VE303 Ph2 study in CDI. #IDWeek2024

This analysis show the positive impact of VE303 treatment on the levels of antibiotic resistance genes in the gut microbiomes of patients enrolled in the Ph2 CONSORTIUM study, revealing associations between higher dosage and colonization of VE303 strains with lower levels of ARGs

@themissingmenon will be giving the late-breaking oral presentation this Friday in LA as part of Infectious Diseases Week (IDWeek) 2024

Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes businesswire.com/news/home/2024…

We are recruiting a Bioinformatician to join our Systems Biology team at Vedanta. Come work with us to advance defined bacterial consortia as a new drug modality! job-boards.greenhouse.io/vedantabioscie…

I am looking to hire a Bioinformatics Scientist to join the Systems Biology team @VedantaBio. Considering candidates in Boston area and up to 100% remote, if in US. Apply today! Please share! job-boards.greenhouse.io/vedantabioscie…

𝐓𝐚𝐥𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: @VedantaBio's founder and CEO @bernatolle shares an expert take on microbiome drug development. Full video: biotechtv.com/post/vedanta-b…

We are excited to announce the publication of our new article today: nature.com/articles/s4158…

Exciting collab with @Honda1Kenya’s lab, out today in @Nature: A set of microbial strains taken from a human faecal donor can decolonize multidrug-resistant Enterobacteriaceae in the gut, including species associated with #IBD. (1/3) nature.com/articles/s4158…

Welcome @Christof_Marre and Steve Shiff to the @VedantaBio team! businesswire.com/news/home/2024…

We did not have a blueprint for how to get an LBP ready for a registrational study. In the last couple of years, the process development, analytical development, manufacturing, and quality teams @vedantabio worked tirelessly navigating uncharted waters /7

The Phase 3 study, RESTORATiVE303, is now underway in the US. We plan to expand enrollment to include >20 countries. It is a registrational study designed to support a BLA submission /6

In the Phase 2 CONSORTIUM Study, VE303 demonstrated strong evidence of efficacy and a good safety profile, and so the VE303 high dose has been advanced to Phase 3 development /5

VE303 is a potential first-in-class Live Biotherapeutic Product consisting of an 8-strain defined bacterial consortium. "Defined" means the product has a specific, known composition of bacterial strains. Each capsule contains the same strains, at a consistent dose /4

Fecal Microbiota Products are made from donor feces. We believe this has inherent limitations around commercial scalability, risk of pathogen transfer, and batch-to-batch variability. We hope to advance the field with DEFINED products which obviate the need for donors /3

FDA has approved two Fecal Microbiota Products for rCDI, which provide patients access to an alternative to unregulated FMT fda.gov/vaccines-blood… /2